

# Open Clinical Trials

May 2026

To refer a patient, please contact the disease specific nurse navigator directly to schedule a visit with one of our providers.

Please note that slot status may vary over time.

For more information regarding trials at the University of Colorado, please visit:

<https://researchstudies.cuanschutz.edu/>

## Jump to Cancer Types

- [Breast](#)
- [Cutaneous](#)
- [Gastrointestinal](#)
- [Genitourinary](#)
- [Gynecologic](#)
- [Head and Neck](#)
- [Hematology](#)
- [Neuro-Oncology](#)
- [Phase 1, Expansion, Molecular Studies \(POEMs\)](#)
- [Radiation Oncology](#)
- [Sarcoma](#)
- [Thoracic \(Lung\)](#)

### [Common Eligibility Criteria for Clinical Trials](#)

Location Key	
AMC	Anschutz Medical Campus, Anschutz Cancer Pavilion, 1665 Aurora Ct, Aurora, CO 80045
CCMC	Cherry Creek Medical Center, 100 Cook St, Denver, CO 80206
HRH	Highlands Ranch Hospital, 1500 Park Central Dr, Highlands Ranch, CO 80129
LT	Lone Tree Medical Center, 9548 Park Meadows Dr, Lone Tree, CO 80124

### [Satellite Site Contacts](#)



Breast Cancer Medical Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Jane Jachowicz, BSN, RN	Jane.jachowicz@uchealth.org	Phone: 720-848-3537 Fax: 720-848-1774
Sara Johnson, BSN, RN	Sara.johnson@uchealth.org	Phone: 720-848-9237 Fax: 720-848-1774
Physician Leads	Email	Phone
Virginia Borges, MD	Virginia.borges@cuanschutz.edu	
Peter Kabos, MD	Peter.kabos@cuanschutz.edu	
Jennifer Diamond, MD	Jennifer.diamond@cuanschutz.edu	

Metastatic Breast Cancer			
Study Name	Patients	NCT#	Sites
Phase I study of OP-1250 (Palazestrant) with ribociclib, alpelisib, everolimus, or atirmociclib (22-1277)	Advanced/Metastatic ER+, HER2- breast cancer	<a href="#">NCT05508906</a>	AMC
PRE-I-SPY Phase 1/1b Platform, PRE-Investigation of Serial Studies (24-1242)	Previously treated metastatic breast cancer	<a href="#">NCT05868226</a>	AMC
Phase 3 trial of saruparib (PARP1i) plus camizestrant (SERD) vs MD choice of CDK4/6 plus endocrine therapy (24-1711)	ER+, HER2-, BRCA1, BRCA2 or PALB2 mutations	<a href="#">NCT06380751</a>	AMC
Phase 3 Study of MK-2870 (Sac-TMT, ADC) +/- pembromizumab vs physician's choice therapy (24-1416)	HR+/HER2-negative metastatic breast cancer	<a href="#">NCT06312176</a>	AMC CCMC HRH
Phase 2 trial of nab-paclitaxel, durvalumab, tremelimumab +/- vaccine (19-0013)	1L metastatic TNBC	<a href="#">NCT03606967</a>	AMC
Phase 2 study of tucatinib, eribulin, trastuzumab (22-1407)	Previously treated metastatic HER2+ breast cancer	<a href="#">NCT05458674</a>	AMC
Phase 3 CDK4/6i + fulvestrant +/- capivasertib (AKTi) (21-3077)	1L metastatic HR+HER2- breast cancer	<a href="#">NCT04862663</a>	AMC, CCMC
Phase 1 study of STX-478 (mutant selective PI3K inhibitor) (23-0200)	Metastatic HR+HER2- breast cancer with PIK3CA mutation	<a href="#">NCT05768139</a>	AMC (POEMs)
Phase 3 study OP-1250 (SERD) (23-2036)	Metastatic HR+HER2-	<a href="#">NCT06016738</a>	AMC, HRH, CCMC, LT
Phase 3 study of zanidatamab (HER2 bispecific ab) + standard therapy v. trastuzumab + standard therapy (24-1635)	Previously treated metastatic HER2+ breast cancer	<a href="#">NCT06435429</a>	AMC, HRH, CCMC
Phase 1 study of BG-C9074 (B7H4 ADC Topoi) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, ovarian cancer, no prior Topoi ADC	<a href="#">NCT06233942</a>	AMC (POEMs)
Phase 1/2 study of MBRC-101 (EphA5 ADC MMAE) in select advanced solid tumors (23-2430)	Metastatic breast cancer	<a href="#">NCT06014658</a>	AMC (POEMs)
CDK4/6 Inhibitor dosing knowledge (CDK) study (24-1798)	Metastatic breast cancer in older adults	<a href="#">NCT06377852</a>	AMC



Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	<a href="#">NCT06253871</a>	AMC (POEMs)
Phase II study of utidelone (UTD1) + capecitabine (25-0715)	HER2-negative Metastatic Breast Cancer Patients with Brain Metastases	<a href="#">NCT06764940</a>	AMC
Phase Ib Study of bulumtaturg fvedotin (Nectin-4 ADC MMAE) in previously treated metastatic TNBC (25-1309)	Previously treated metastatic TNBC, requires prior Topoi ADC and taxane	<a href="#">NCT06908928</a>	AMC
Phase I study of DPTX3186 (Wnt/B-catenin inhibitor) Wnt-Pathway Activated Solid Tumors (25-2381)	Solid Tumors known to be Wnt-Pathway activated (Gastric, TNBC) with no other approved treatment options available	<a href="#">NCT07312903</a>	AMC (POEMs)
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer (24-1686)	HR+, HER2 – metastatic adenocarcinoma of breast not amenable to curative therapy. Progression with at least 2 prior lines of endocrine therapy, no prior chemotherapy	<a href="#">NCT06369285</a>	AMC, HRH, CCMC
<b>Early-Stage Breast Cancer</b>			
ISPY2.2 neoadjuvant study (10-0374)	Stage II-III Breast cancer	<a href="#">NCT01042379</a>	AMC, LT, HRH, CCMC
DARE: Phase 2 trial of ctDNA-guided treatment (20-2773)	High risk HR+HER2-	<a href="#">NCT04567420</a>	AMC, LT, HRH, CCMC
OFSET: Phase 3 study of chemotherapy v. ovarian suppression (23-2461)	Premenopausal HR+HER2-breast cancer	<a href="#">NCT05879926</a>	AMC, LT, HRH, CCMC
OptimICE-PCR: De-escalation after pCR (23-1255)	TNBC with pCR to neoadjuvant therapy	<a href="#">NCT05812807</a>	AMC, LT, HRH
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0 breast cancer (19-0476)	Low-risk node+ or T3N0M0 breast cancer following surgery	<a href="#">NCT03488693</a>	AMC, CCMC, HRH, LT (RT Group)
S2206: Phase 3 trial of neoadjuvant durvalumab (PD-L1i) plus chemo vs chemo alone (24-0401)	MammaPrint ultrahigh ER/PR+, HER2-	<a href="#">NCT06058377</a>	AMC, LT, HRH, CCMC
S2212 SCARLET: Shorter Anthracycline-Free Chemo Immunotherapy in Early TNBC (23-2438)	Early Stage TNBC	<a href="#">NCT05929768</a>	AMC, CCMC LT HRH
A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade (25-2075)	Clinical Stage T1c-T3 N0-N1 (except T3N1) with pCR after neoadjuvant therapy (HER2+)	<a href="#">NCT06876714</a>	AMC, CCMC LT HRH

<b>Cutaneous Oncology Anschutz Medical Campus (AMC)</b>		
<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Nurse navigator	melanoma@uchealth.org	Phone: 720-848-0505 Fax: 720-848-0614
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Sapna Patel, MD	Sapna.p.patel@cuanschutz.edu	

**High-Risk Resected Melanoma  
No current trials available**

**Advanced Melanoma**

Phase 2/3 study of LNS8801 (GPER agonist) +/- without pembrolizumab (25-0336)	Treatment refractory, unresectable melanoma	<a href="#">NCT06624644</a>	AMC
TILVANCE-301: Phase 3 trial of Lifileucel (LN-144 tumor infiltrating lymphocyte) + pembro vs pembro alone (24-0982)	Untreated, unresectable or metastatic melanoma	<a href="#">NCT05727904</a>	AMC
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50% 1L PD-L1+ melanoma 2L PD-L1+ melanoma	<a href="#">NCT05533697</a>	AMC (POEMs)
IGNYTE-3: Phase 3 trial of vusolimogene oderparepvec (oncolytic virus) + nivolumab v. treatment of physician's choice (24-1672)	Advanced melanoma progressed on Anti-PD-1 and Anti-CTLA-4	<a href="#">NCT06264180</a>	AMC
Phase 3 trial of fianlimab + cemiplimab vs relatlimab (LAG-3i) and nivolumab (24-1713)	Unresectable or metastatic melanoma	<a href="#">NCT06246916</a>	AMC
SUPRAME: Phase 3 study of IMA203 (autologous T-cell receptor-engineered T cell therapy targeting PRAME) versus investigator's choice in patients with melanoma (25-0844)	Unresectable or previously treated cutaneous melanoma; HLA-A*02:01 positive, Disease progression (resistance or toxicity) on at least 1 PD-1 inhibitor	<a href="#">NCT06743126</a>	AMC
A Phase 1b/2a study of Oral 7HP349 (Alintegimod, immunomodulator) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies (25-0578)	Locally Advanced or metastatic Melanoma	<a href="#">NCT06362369</a>	AMC
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101) (25-2206)	Recurrent/progressing melanoma that has received or not eligible for all SOC. HLA-A*02:01 positive	<a href="#">NCT03686124</a>	AMC

**Neoadjuvant or Resectable Melanoma/**

**Uveal Melanoma**

OptimUM-10: Phase 3 study of neoadjuvant darovasertib (PKCi) in patients with non-metastatic uveal melanoma (25-2370)	Non-metastatic uveal melanoma	<a href="#">NCT07015190</a>	AMC
TARGET-Tebe: A Phase II Study of KIMMTRAK (bispecific T-cell engager) in HLA-A*0201 positive untreated metastatic uveal melanoma (25-2068)	Untreated metastatic uveal melanoma positive for HLA-A*0201	<a href="#">NCT06070012</a>	AMC

Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101) (25-2206)	Recurrent and/or refractory uveal melanoma	<a href="#">NCT03686124</a>	AMC
REVEAL: Phase 2/3 Study of RP2 (oncolytic virus) + nivolumab v. ipilimumab + nivolumab (25-0004)	Immune checkpoint inhibitor-naïve metastatic uveal melanoma; no more than 2 lines of systemic therapy	<a href="#">NCT06581406</a>	AMC
<b>Merkel Cell Carcinoma, Squamous Cell Carcinoma</b>			
Clinical trial of IFx-Hu2.0 (cancer vaccine) added to pembro in IO naïve merkel cell carcinoma (25-0580)	Advanced or metastatic merkel cell carcinoma	<a href="#">NCT06947928</a>	AMC
Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy	<a href="#">NCT07080242</a>	AMC (POEMs)
NRG14-HN014: Phase 3 trial of neoadjuvant IO with response adapted treatment v. SOC for resectable Stage III/IV cutaneous squamous cell carcinoma (CSCC) (25-1924)	Invasive CSCC or regional lymph node or in-transit metastasis of CSCC	<a href="#">NCT06568172</a>	AMC (RT)
<b>Advanced Cutaneous Malignancies in Transplant Recipients</b>			
Phase 1b/2 study of RP1 (oncolytic virus) (19-2987)	Solid organ or hematopoietic cell transplant recipient	<a href="#">NCT04349436</a>	AMC

Gastrointestinal Oncology Anschutz Medical Campus (AMC)		
Nurse Navigators	Email	Phone
Kristen Miller	Kristen.Miller3@uchealth.org	Phone: 720-848-2639
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Marcela Mora (Spanish speaking)	<a href="mailto:Marcela.Mora@uchealth.org">Marcela.Mora@uchealth.org</a>	Phone: 720-848-5474
Physicians	Email	Phone
Lindsey Davis, MD	Sarah.Davis@cuanschutz.edu	
Chris Lieu, MD	Christopher.Lieu@cuanschutz.edu	
Wells Messersmith, MD	Wells.Messersmith@cuanschutz.edu	

Gastric, Gastroesophageal, and Gastroesophageal Junction (GEJ) Cancers			
Phase 3 study of rilvegostomig (bispecific ab) + fluoropyrimidine + trastuzumab deruxtecan v. trastuzumab, chemotherapy + pembrolizumab (ARTEMIDE-Gastric01/25-0646) (25-0646)	1L HER2 gastric cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06764875">NCT06764875</a>	AMC
Phase 1 study of SGN-CEACAM5C (CEACAM5 ADC Topoi) advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06131840">NCT06131840</a>	AMC
Phase 1 study of TJ033721 (Givastomig, Claudin 18.2 x 4-1BB bispecific ab) in metastatic gastric, GE and esophageal adenocarcinoma (21-3254)	1L metastatic gastric, GE, and esophageal adeno ca positive for CLDN18.2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04900818">NCT04900818</a>	AMC
CHS-114-102: Phase 1b study of CHS-114 (anti-CCR8ab) + toripalimab +/- other treatments (25-1556)	2L Gastric, GEJ and Esophageal Adenocarcinoma and 2L esophageal squamous cell carcinoma	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06657144">NCT06657144</a>	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06253871">NCT06253871</a>	AMC (POEMs)
Phase I study of DPTX3186 (Wnt/B-catenin inhibitor) Wnt-Pathway Activated Solid Tumors (25-2381)	Solid Tumors known to be Wnt-Pathway activated (Gastric, TNBC, CRC) with no other approved treatment options available	<a href="https://clinicaltrials.gov/ct2/show/study/NCT07312903">NCT07312903</a>	AMC (POEMs)
BL-M05D1-ST-101: A Phase 1 study of BL-M05D1 (Claudin 18.2 ADC Topoi) in advanced solid tumors (25-1878)	2L + Gastric, GEJ or Esophageal Adenocarcinoma, 2L+ biliary cancers	<a href="https://clinicaltrials.gov/ct2/show/study/NCT07021066">NCT07021066</a>	AMC
EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II (25-2369)	MSS gastric or GEJ Adenocarcinoma (cyt+) or peritoneal carcinomatosis. Must have received min 3 months and max 6 months of 1L systemic treatment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT07001748">NCT07001748</a>	AMC



Early-Stage Colorectal Cancer (CRC)			
CIRCULATE-US: Colon adjuvant chemotherapy based on evaluation of residual disease (22-0916)	Stage IIIA/B MSS colon adenocarcinoma following curative resection	<a href="#">NCT05174169</a>	AMC, LT, HRH, CCMC
Phase 2 Single-Arm Rectal Cancer brachytherapy for patients with low-lying residual adenocarcinoma after total neoadjuvant therapy to improve organ preservation rates (25-1202)	MMR-Proficient low-mid rectal adenocarcinoma cT1-4, N0-2, M0	<a href="#">NCT07292298</a>	AMC (RT Group)
Metastatic Colorectal Cancer (CRC)			
Phase I trial of AWN003694 + cetuximab + encorafenib (25-0300)	Refractory BRAF V600E metastatic CRC	<a href="#">NCT06102902</a>	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies (24-1326)	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	<a href="#">NCT06445062</a>	AMC, LT
OrigAMI-3: Phase 3 study of FOLFIRI + amivantamab v cetuximab/bevacizumab in metastatic CRC (24-2380)	2L metastatic CRC KRAS/NRAS and BRAF WT	<a href="#">NCT06750094</a>	AMC
INTRINSIC: Phase 1/1b umbrella study of targeted therapies in metastatic CRC (21-3774)	Previously treated advanced or metastatic CRC with PIK3CA mutation +/- RAS mutation	<a href="#">NCT04929223</a>	AMC
CARAPIA-1: Phase 1 study of GCC19CART in metastatic CRC. <i>This trial requires hospitalization and inpatient delivery of study drug for some cycles</i> (22-0697)	Previously treated metastatic CRC, GCC+, MSS	<a href="#">NCT05319314</a>	AMC
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations (22-1125)	Metastatic CRC with BRAF V600E mutation	<a href="#">NCT05355701</a>	AMC (POEMs)
Phase 1 study of SGN-CEACAM5C (CEACAM5 ADC Topoi) advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="#">NCT06131840</a>	AMC
AE2222: PUMP: Phase 3 study of systemic therapy +/- hepatic arterial infusion for unresectable CRC liver mets (24-0029)	Unresectable liver metastatic CRC	<a href="#">NCT05863195</a>	AMC
Phase 1 study of JNJ-89402638 (bispecific ab) for metastatic CRC (24-1600)	3L+ unresectable metastatic CRC	<a href="#">NCT06663319</a>	AMC
Phase 1 study of BI1831169 (oncolytic virus) +/- ezabenlimab (anti-PD-1) in advanced solid GI tumors (23-2048)	Advanced or metastatic GI tumors with no standard therapies	<a href="#">NCT05155332</a>	AMC
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations	<a href="#">NCT06447662</a>	AMC (POEMs)
CHS-114-102: Phase 1b study of CHS-114 (anti-CCR8) + toripalimab with or without other treatments in participants with advanced or metastatic solid tumors (25-1556)	4L + CRC	<a href="#">NCT06657144</a>	AMC
Phase I study of DPTX3186 (Wnt/B-catenin inhibitor) Wnt-Pathway Activated Solid Tumors (25-2381)	Solid Tumors known to be Wnt-Pathway activated (Gastric, TNBC, CRC) with no other approved treatment options available	<a href="#">NCT07312903</a>	AMC (POEMs)

DSP107_003: Phase 2b study of DSP107 (bi-specific 4-1BB T-cell engager) + atezolizumab v. fruquintinib in advanced microsatellite stable CRC (26-0039)	MSS or pMMR CRC progressed or intolerant to 5FU, oxaliplatin, irinotecan, anti-VEGF and anti-EGFR (if RAS WT). No more than 3 prior lines of therapy	<a href="#">NCT07235293</a>	AMC, HRH
MRG007-001/ARR-217-101: Phase 1 study of MRG007 (ARR-217, CDH17 ADC) in advanced solid tumors (25-2495)	Advanced or metastatic solid tumor that has failed or intolerant to standard therapy	<a href="#">NCT07066657</a>	AMC
<b>Liver Cancer</b>			
Phase 1b/2 study of multiple immunotherapy based treatment combinations (24-1787)	Locally advanced/metastatic /unresectable HCC; no priory treatment	<a href="#">NCT04524871</a>	AMC, HRH, CCMC
Phase 1b/2 study of TTI-101 (STAT3i) in advanced or metastatic HCC (22-1621)	1-3L Unresectable, locally advanced or metastatic HCC	<a href="#">NCT05440708</a>	AMC
BL-M05D1-ST-101: A Phase 1 study of BL-M05D1 (Claudin 18.2 ADC Topoi) in advanced solid tumors (25-1878)	2L + Gastric, GEJ or Esophageal Adenocarcinoma, 2L+ biliary cancers	<a href="#">NCT07021066</a>	AMC
<b>Biliary Tract Cancer</b>			
Protocol 10608, A phase II trial of durvalumab with gemcitabine and cisplatin as neoadjuvant therapy for high-risk resectable intrahepatic cholangiocarcinoma (24-0573)	Resectable intrahepatic cholangiocarcinoma	<a href="#">NCT06050252</a>	AMC
Phase 1/2 study of patritumab deruxtecan (ADC) (24-1883)	2L + Biliary Tract Cancer	<a href="#">NCT06596694</a>	AMC
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (24-1250)	Cohort 3 – 2L Biliary Tract Cancer Cohort 4 – 1L Biliary Tract Cancer	<a href="#">NCT06428409</a>	AMC, HRH, CCMC
<b>Pancreatic Cancer</b>			
Intraperitoneal paclitaxel for pancreatic ductal adenocarcinoma (24-2111)	Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis	<a href="#">NCT07030283</a>	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies (24-1326)	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	<a href="#">NCT06445062</a>	AMC, LT
Phase 1/2 study of M3814 + hypofractionated radiation for locally advanced pancreatic adenocarcinoma (20-2093)	Locally advanced pancreatic adenocarcinoma following 4-6 months of neoadjuvant chemo	<a href="#">NCT04172532</a>	AMC
Phase 1 study of SGN-CEACAM5C (CEACAM5 ADC Topoi) advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	<a href="#">NCT06131840</a>	AMC
Phase 1 study of CA-4948 (IRAK4/FLT3i) + gemcitabine+ nab-paclitaxel in metastatic pancreatic cancer (23-0613)	2-3L metastatic or unresectable pancreatic ductal adeno	<a href="#">NCT05685602</a>	AMC

A Phase 1A/B Study to Evaluate the Safety and Tolerability Of EBC-129 (CEACAM5/6 ADC) As A Single Agent and In Combination with Pembrolizumab in Advanced Solid Tumors (23-0580)	Metastatic Pancreatic Adenocarcinoma	<a href="#">NCT05701527</a>	AMC (POEMs)
MRG007-001/ARR-217-101: Phase 1 study of MRG007 (ARR-217, CDH17 ADC) in advanced solid tumors (25-2495)	Advanced or metastatic solid tumor that has failed or intolerant to standard therapy	<a href="#">NCT07066657</a>	AMC
223675: A Phase1b/2 study of GSK5764227 (B7-H3 ADC Topoi) alone and in combination in previously treated advanced unresectable or metastatic gastrointestinal solid tumors (25-1442)	2L Pancreatic adenocarcinoma (irinotecan naive)	<a href="#">NCT06885034</a>	AMC
BL-M05D1-ST-101: A Phase 1 study of BL-M05D1 (Claudin 18.2 ADC Topoi) in advanced solid tumors (25-1878)	2L+ Pancreas Adenocarcinoma	<a href="#">NCT07021066</a>	AMC
<b>Neuroendocrine Cancers</b>			
COMPOSE: Study of peptide receptor radionuclide therapy with lutetium edotreotide v standard therapy for SSTR+ GI neuroendocrine tumors (21-3552)	Well-differentiated aggressive, grade 2/3, SSTR+ neuroendocrine tumors of gastroenteric or pancreatic origin	<a href="#">NCT04919226</a>	AMC
NET Retreat: Phase 2 study of 177Lutetium retreatment v. everolimus in metastatic midgut neuroendocrine (23-1917)	Metastatic grade 1/2 midgut neuroendocrine tumors	<a href="#">NCT05773274</a>	AMC
Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy	<a href="#">NCT07080242</a>	AMC (POEMs)

<b>Genitourinary Oncology Anschutz Medical Campus (AMC)</b>		
<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Cyndie Harvey	Cynthia.Harvey@uchealth.org	Phone: 720-848-0170 Fax: 720-848-0180
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Laura Graham, MD	Laura.graham@cuanschutz.edu	
Elizabeth Kessler, MD	Elizabeth.kessler@cuanschutz.edu	

<b>Localized Prostate Cancer</b>			
<b>Study Name</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
S2210: Neoadjuvant carboplatin for patients with localized prostate cancer and germline BRCA1/2 mutations (23-2420)	Localized prostate cancer with germline BRCA1/2 mutation	<a href="#">NCT05806515</a>	AMC
Pragmatic study of metformin v. lifestyle mods (19-1536)	Localized prostate cancer	<a href="#">NCT05515978</a>	AMC
<b>Metastatic Prostate Cancer</b>			
S1802: SST +/- surgery or radiation (18-2252)	Metastatic hormone sensitive prostate cancer	<a href="#">NCT03678025</a>	AMC
NRG GU011: PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy (22-0504)	Oligometastatic hormone sensitive prostate cancer	<a href="#">NCT05053152</a>	AMC, HRH (RT Group)
KEYNOTE-365: Study of pembrolizumab combinations COHORT I: Carbo/Etop +/- pembro (21-3724)	De novo and treatment emergent neuroendocrine/small cell prostate cancer	<a href="#">NCT02861573</a>	AMC
MK-5684-003: Phase 3 study of opevesostat v. abiraterone/enzalutamide (24-0350)	Metastatic castration-resistant prostate cancer previously treated with hormonal agent and taxane	<a href="#">NCT06136624</a>	AMC, HRH, LT
MK-5684-004: Phase 3 study of opevesostat v. abiraterone/enzalutamide (24-0742)	Metastatic castration-resistant prostate cancer previously treated with hormonal agent	<a href="#">NCT06136650</a>	AMC, HRH, LT
JNJ-87189401 and JNJ-78278343 (23-1990)	Metastatic castration-resistant prostate cancer	<a href="#">NCT06095089</a>	AMC
Phase 1b/2a study of pocenbrodib alone or in combination with abiraterone acetate, olaparib, or 177Lu-PSMA-617 (24-2278)	Metastatic castration-resistant Prostate Cancer	<a href="#">NCT06785636</a>	AMC
CCTG-PR26 - Randomized phase 3 clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors (TRIPLE-SWITCH) (25-0680)	Metastatic castration-sensitive prostate cancer and suboptimal PSA response	<a href="#">NCT06592924</a>	AMC CCMC LT HRH
Phase 3 study of pasritamig (JNJ-78278343), a T-cell-redirecting agent targeting human kallikrein 2 v best supportive care for metastatic castration-resistant prostate cancer (25-1528)	Metastatic castration-resistant Prostate Cancer	<a href="#">NCT07164443</a>	AMC
Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine	<a href="#">NCT07080242</a>	AMC (POEMs)



	neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy		
<b>Bladder Cancer</b>			
Phase 2 study of intravesicular instillation of TARA-002 (24-1264)	High grade non-muscle invasive bladder cancer	<a href="#">NCT05085990</a>	AMC
EA8192 Preoperative durvalumab and/or chemo (21-3855)	Upper tract urothelial cancer	<a href="#">NCT04628767</a>	AMC
MODERN: A032103 risk adapted adjuvant therapy - ctDNA testing and nivo+/- relatlimab or surveillance (24-0700)	Muscle invasive bladder cancer or upper tract urothelial cancer after surgery	<a href="#">NCT05987241</a>	AMC
S1937: Eribulin + gemcitabine v. standard therapy (22-0927)	3L+ metastatic bladder cancer post PD1i	<a href="#">NCT04579224</a>	AMC
NRG-GU015: Phase 3 trial of adaptive RT + chemo for muscle invasive bladder cancer (ARCHER) (25-2502)	CT2-T3,N0M0 Urothelial carcinoma of bladder	<a href="#">NCT07097142</a>	AMC (RT)
S2427: Phase 2 study of bladder preservation with immunoradiotherapy after clinically meaningful response to neoadj therapy in muscle invasive bladder cancer (BRIGHT) (25-2505)	CT2-T4aN0M0 muscle invasive urothelial carcinoma of bladder	<a href="#">NCT07061964</a>	AMC (RT)
<b>Kidney Cancer</b>			
SAMURAI: Phase 2 study of SABR in patients receiving immunotherapy (24-2480)	Metastatic unresectable RCC	<a href="#">NCT05327686</a>	AMC LT HRH CCMC
NEOPAX: Pembrolizumab + axitinib for RCC with IVC tumor thrombus (22-1669)	Neoadjuvant therapy for RCC with tumor thrombus	<a href="#">NCT05969496</a>	AMC
HC-7366 + belzutifan for locally advanced or metastatic clear cell RCC (24-0745)	2L+ metastatic clear cell RCC	<a href="#">NCT06234605</a>	AMC
STRIKE/A032201: Study of short term intensified pembrolizumab + tivozanib for high-risk renal cell carcinoma (25-0682)	Clear cell RCC following complete resection	<a href="#">NCT06661720</a>	AMC HRH CCMC LT
A092204: Phase 2 study of cabozantinib + cemiplimab v cabozantinib in adolescents and adults with advanced adrenocortical cancer (25-2801)	Locally advanced unresectable or recurrent/metastatic adrenocortical carcinoma	<a href="#">NCT06900595</a>	AMC
<b>Penile Cancer</b>			
EA8134 InPACT: Neoadjuvant chemo + ILND v chemo +RT+ILND v ILND (17-1515)	Penile cancer	<a href="#">NCT02305654</a>	AMC

<b>Gynecologic Oncology Anschutz Medical Campus (AMC)</b>			
<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>	
Clinic schedulers		Phone: 303-724-2066	
Marcela Mora (Spanish speaking)	<a href="mailto:Marcela.Mora@uchealth.org">Marcela.Mora@uchealth.org</a>	Phone: 720-848-5474	
<b>Physician</b>	<b>Email</b>	<b>Phone</b>	
Brad Corr, MD	<a href="mailto:Bradley.corr@cuanschutz.edu">Bradley.corr@cuanschutz.edu</a>		
<b>Ovarian Cancer - Frontline</b>			
<b>Study</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
GOG-3068 HOTT HIPEC: Phase 3 study of HIPEC + cisplatin v no HIPEC at time of cytoreductive surgery followed by niraparib in stage III and IV ovarian cancer (23-2189)	Newly diagnosed stage III/IV ovarian, primary peritoneal, and fallopian tube cancer treated with neoadj chemo	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05659381">NCT05659381</a>	AMC
<b>Ovarian Cancer - Maintenance</b>			
UPROAR: Phase 2 study of maintenance mirvetuximab soravtansine (ADC) and olaparib in recurrent platinum sensitive, ovarian cancer (22-0384)	Recurrent platinum-sensitive ovarian, peritoneal, and fallopian tube cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05887609">NCT05887609</a>	AMC
NRG-GY036: Phase 3 trial of one vs. two years maintenance olaparib, +/- bevacizumab (25-0399)	BRCA1/2 mutated or HRD+ ovarian cancer following response to 1L platinum-based chemotherapy	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06580314">NCT06580314</a>	AMC CCMC HRH
<b>Ovarian Cancer - Recurrent</b>			
VOLAstra: Phase 1/2 study of VLS-1488 (KIF18Ai) in advanced high grade serous ovarian cancer (23-1991)	CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05902988">NCT05902988</a>	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, endometrial, or ovarian cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06233942">NCT06233942</a>	AMC (POEMs)
A Phase 1b study of psilocybin assisted psychotherapy to address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission (23-1455)	Clinical stage 1 or 2, completed primary treatment, risk of recurrence at 10 years <20%	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06430541">NCT06430541</a>	AMC
Phase I study of CLK/DYRK (Cirtuvivint) + olaparib in BRCA/HRD platinum resistant ovarian cancer (24-1749)	Platinum-resistant ovarian cancer with 1-3 prior lines of therapy. BRCA or HRD + with prior parp inhibitor.	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06856499">NCT06856499</a>	AMC
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic refractory Ovarian Adenocarcinoma	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06014658">NCT06014658</a>	AMC (POEMs)
Phase 2 Trial of the combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor talazoparib, in patients with	HRD tumors with prior PARPi use as immediate prior therapy	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05327010">NCT05327010</a>	AMC (POEMs)

molecularly selected solid tumors (ComBET) (23-0145)			
<b>Ovarian Cancer – Low Grade</b>			
No current studies available			
<b>Endometrial Cancer - Presurgical</b>			
No current studies available			
<b>Endometrial Cancer - Frontline</b>			
NRG GY026: Phase 2/3 study of paclitaxel/carboplatin +/- hylecta or phesgo in HER2+ endometrial cancer (22-1764)	1L Stage I-IV endometrial serous carcinoma, carcinosarcoma, or other histology HER2+	<a href="#">NCT05256225</a>	AMC, HRH, CCMC
NRG GY032: Phase 2 study of tailored adjuvant therapy in POLE-mutated p53 WT early-stage endometrial cancer (24-1417)	1L Stage I-III endometrial cancer POLE-mutated, p53 WT, completed surgery	<a href="#">NCT06388018</a>	AMC
<b>Endometrial Cancer - Recurrent</b>			
GOG-3082: Phase 1b/2 basket study of ACR-368 (CHK1/2i) +/-gemcitabine in platinum-resistant ovarian, endometrial and urothelial ca based on acrivon oncosignature (23-0115)	Up to 2L in recurrent setting: Recurrent, platinum-resistant ovarian cancer, endometrial adenoca, urothelial carcinoma with Acrivol Oncosignature Status	<a href="#">NCT05548296</a>	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, endometrial, or ovarian cancer	<a href="#">NCT06233942</a>	AMC (POEMs)
<b>Cervical Cancer</b>			
NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer (25-2515)	High Risk Locally Advanced Cervical Cancer	<a href="#">NCT07061977</a>	AMC, HRH
<b>Uterine Leiomyosarcoma</b>			
GOG 3088: Phase 2 study of letrozole v. observation in uterine leiomyosarcoma (24-0041)	Newly diagnosed ER+ uterine leiomyosarcoma	<a href="#">NCT05649956</a>	AMC, HRH
<b>BRCA Mutation Carriers</b>			
SOROC: Study of salpingectomy v. salpingo-oophorectomy to reduce risk of ovarian cancer in BRCA1 carriers (20-2079)	BRCA1 germline mutation carriers with no prior cancer diagnosis age 35-50	<a href="#">NCT04251052</a>	AMC, HRH

Head and Neck Cancer Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Kristen Miller	Kristen.Miller3@uchealth.org	Phone: 720-848-2639
Natalya Veneychuk	<a href="mailto:Natalya.Veneychuk@uchealth.org">Natalya.Veneychuk@uchealth.org</a>	Phone: 720-848-5456
Marcela Mora (Spanish speaking)	<a href="mailto:Marcela.Mora@uchealth.org">Marcela.Mora@uchealth.org</a>	Phone: 720-848-5474
Physician	Email	Phone
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	

Head and Neck Cancer			
Study Name	Patients	NCT#	Sites
Phase 1b/2 study of NT219 in combination with pembro or cetuximab (24-0689)	Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06919666">NCT06919666</a>	AMC, HRH
FORTIFI-HN010: Phase 2/3 study of ficerafusp alfa (BCA101) v. placebo + pembrolizumab (25-0122)	1L PD-L1-positive, recurrent or metastatic HNSCC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06788990">NCT06788990</a>	AMC
eVOLVE-HNSCC: Phase 3 study of volrustomig v. observation in unresected locally advanced HNSCC (23-2332)	Unresected locally advanced HNSCC who have not progressed following definitive concurrent chemoRT	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06129864">NCT06129864</a>	AMC, HRH
OrigAMI-4: Phase 1b/2 study of amivantamab monotherapy + standard therapy in recurrent/metastatic HNSCC (24-0472)	Locally Advanced treatment naive and eligible for surgery HNSCC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06385080">NCT06385080</a>	AMC
Phase 1b study of losartan, pembrolizumab and SBRT in locoregionally recurrent refractory or oligometastatic HNSCC (24-1630)	locoregionally recurrent refractory or oligometastatic HNSCC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06211335">NCT06211335</a>	AMC, HRH
NRG- HN010: Phase 2 study of docetaxel + trastuzumab v. T-DM1 for HER2+ salivary gland cancer (22-2363)	Recurrent, metastatic, or treatment-naïve, unresectable HER2+ salivary gland cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05408845">NCT05408845</a>	AMC, HRH
EA3231: Phase 3 study of BRAF-targeted therapy v. cabozantinib in RAI-refractory differentiated thyroid cancers with BRAF V600E mutation (24-2273)	Advanced RAI-refractory differentiated thyroid cancers with BRAF V600E mutation	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06475989">NCT06475989</a>	AMC, HRH
A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma (25-1457)	Pheochromocytoma or paraganglioma that is unresectable and failed or declined SOC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT07282587">NCT07282587</a>	AMC



Hematology Clinical Trials Unit Anschutz Medical Campus (AMC)		
<b>Nurse Navigator</b> UCH-BDC Intake Team	<b>Email</b> <a href="mailto:UCH-BDCIntakeTeam20181018184924@uchealth.org">UCH-BDCIntakeTeam20181018184924@uchealth.org</a>	<b>Phone</b> 720-848-2595
<b>Doc Line Phone:</b> 720-848-2628 (doc line)		
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
<b>Leukemia:</b> Dan Pollyea, MD	<a href="mailto:Daniel.pollyea@cuanschutz.edu">Daniel.pollyea@cuanschutz.edu</a>	
<b>Cell Therapy/Stem Cell Transplant:</b> Jon Gutman, MD	<a href="mailto:Jonathan.gutman@cuanschutz.edu">Jonathan.gutman@cuanschutz.edu</a>	
<b>Lymphoma:</b> Manali Kamdar, MD	<a href="mailto:Manali.kamdar@cuanschutz.edu">Manali.kamdar@cuanschutz.edu</a>	
<b>Multiple Myeloma:</b> Dan Sherbenou, MD, PhD	<a href="mailto:Daniel.sherbenou@cuanschutz.edu">Daniel.sherbenou@cuanschutz.edu</a>	
<b>Benign Heme and MPNs:</b> Brandon McMahon, MD	<a href="mailto:Brandon.mcmahon@cuanschutz.edu">Brandon.mcmahon@cuanschutz.edu</a>	

Leukemia			
Study	Patients	NCT#	Sites
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (PI: C. McMahon/ 25-0091)	Relapsed and/or refractory CD33 positive AML that has failed initial standard therapy	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06714591">NCT06714591</a>	AMC
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia (PI: C. McMahon/25-1278)	<u>Nonintensive Therapy Study (Ven+Aza)</u> • NPM1-m, >75 years of age, Age <75 and unfit for IC based on comorbidities <u>Intensive Therapy Study (7+3)</u> • NPM1-m or KMT2A-r, Age >18, FLT3 wild-type or ITD ratio <0.05 OR ineligible to receive FLT3-targeted therapy (medically ineligible or mutation in which FLT3 inhibition is not SOC). Lack of access to an FLT3 inhibitor is not considered "ineligible" for FLT3-targeted therapy, Fit for IC per Investigator opinion	<a href="https://clinicaltrials.gov/ct2/show/study/NCT07007312">NCT07007312</a>	AMC
Phase 1b study to evaluate eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (PI: McMahon, C/24-2332)	Relapsed/refractory AML; ECOG of ≤2; adequate organ function	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06533761">NCT06533761</a>	AMC
Phase I study of SNDX-5613 in patients with relapsed/refractory	Relapsed/refractory AML; ECOG of ≤2; adequate organ function	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04065399">NCT04065399</a>	AMC

leukemias including those harboring an MLL/KMT2A gene rearrangement or nucleophosmin1 (NPM1) Mutation (PI: McMahon C/ 22-1050)			
Phase I study of CD19 directed CAR T Cells in adult patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with minimal residual disease (MRD) positivity at first complete remission (PI: Schwartz/22-0054)	Ages $\geq$ 18; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of $\leq$ 2	<a href="#">NCT05535855</a>	AMC
Study of Mitoxantrone for venetoclax-resistant AML (PI: Kent/24-0178)	Non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)	<a href="#">NCT06429449</a>	AMC
A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos/24-1444)	Undergoing allogeneic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	<a href="#">NCT05473910</a>	AMC
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab vs. venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy (PI: McMahon/24-0685)	Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts). Previously untreated AML. Deemed unfit for intensive therapy.	<a href="#">NCT06384261</a>	AMC
Study of cladribine + venetoclax after failure of venetoclax + hypomethylating agent in monocytic AML (PI: McMahon/23-0273)	Ages $\geq$ 18; Relapsed/Refractory AML; ECOG of $\leq$ 2	<a href="#">NCT06232655</a>	AMC
KO-MEN-007: Phase 1 study of venetoclax/azacitidine or venetoclax + ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) + ziftomenib for AML (PI: McMahon/23-0061)	Ages $\geq$ 18; documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML; ECOG of $\leq$ 2	<a href="#">NCT05735184</a>	AMC
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms (PI: Angelos/25-0787)	Diagnosis of either ET or MF as defined by the 2022 WHO criteria. Adequate organ function	<a href="#">NCT06150157</a>	AMC
Phase I/2 Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-D22 Chimeric Antigen Receptor) in patients with relapsed or refractory	Patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)	<a href="#">NCT04150497</a>	AMC

CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL) (PI: Angelos/ 22-1502)			
<b>Myelodysplastic Syndrome Trials</b>			
A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos/24-1444)	Undergoing allogeneic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	<a href="#">NCT05473910</a>	AMC
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia (PI: McMahon, Brandon/25-1397)	DIPSS score of 3 to 4 (intermediate 2 risk) or $\geq 5$ (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria	<a href="#">NCT05320198</a>	AMC
<b>Lymphoma</b>			
Phase I study of patient-derived multi-tumor associated antigen specific T-cells (MT-601) in patients with relapsed/refractory non- hodgkin lymphoma (PI: Kamdar/23-0056)	Diagnosis of NHL, HL or CLL; ECOG or zero or 1; adequate organ function	<a href="#">NCT05798897</a>	AMC
Phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults (PI: Milgrom/24-2065)	Newly diagnosed Stage I and II classic Hodgkins Lymphoma	<a href="#">NCT05675410</a>	AMC (RT Group)
S2308: Randomized Phase 3 study of mosunetuzumab vs. rituximab for low tumor burden follicular lymphoma (PI: Kamdar/ 25-0024)	Participants must have a histologically confirmed diagnosis of Classic Follicular Lymphoma (cFL). Involvement of no more than 3 nodal or extra nodal sites with diameter greater than 3 cm.	<a href="#">NCT06337318</a>	AMC
A Phase 1a/1b trial in relapsed/refractory T-cell non-hodgkin lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for intravenous infusion (PI: Haverkos/24-0458)	Ages > 18; ECOG of 0-1; diagnosed CTCL or Nodal TCL	<a href="#">NCT04234048</a>	AMC
Phase 1b Study of mosunetuzumab or glofitamab + CC-220 and CC-99282 in B-Cell Non-Hodgkin Lymphoma (PI: Kamdar/22-0939)	Ages $\geq 18$ ; ECOG of $\leq 2$	<a href="#">NCT05169515</a>	AMC
Phase 1/1b study of bispecific CD19 and CD22 chimeric antigen receptorCo-expressing T cells (CD19x22 CAR T) in adolescent and	Ages $\geq 16$ ; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1	<a href="#">NCT05098613</a>	AMC

adult patients with relapsed and/or refractory B-NHL (PI: Kamdar/21-2578)			
Phase 3 Study comparing the combination of beleodaq-CHOP or folotyn-COP to the CHOP regimen alone (24-2331)	Newly Diagnosed Patients with Peripheral T-Cell Lymphoma	<a href="#">NCT06072131</a>	AMC
<b>Multiple Myeloma</b>			
A Phase 1, study of CB-011, a CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (CaMMouflage Trial) (PI: Sherbenou/23-0376)	Ages $\geq$ 18; Diagnosed MM and evidence of PD based on IMWG criteria; ECOG of $\leq$ 1	<a href="#">NCT05722418</a>	AMC
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation MajesTEC-4 (PI: Monge/24-2397)	Newly diagnosed MM; post Auto stem cell transplant	<a href="#">NCT05243797</a>	AMC
A phase 1b/2, open-label study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory multiple myeloma remission (PI: Monge Urrea/24-2523)	Ages $\geq$ 18; Received at least three prior MM treatment lines of therapy; Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody	<a href="#">NCT05850234</a>	AMC
<b>Benign Heme</b>			
Phase 3 study of bomedemstat (MK-3543/IMG-7289) v. best available therapy (24-2052)	Essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea	<a href="#">NCT06079879</a>	AMC
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia (PI: McMahon, Brandon/25-1397)	DIPSS score of 3 to 4 (intermediate 2 risk) or $\geq$ 5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria	<a href="#">NCT05320198</a>	AMC
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms (PI: Mat Angelos/25-0787)	Positive for a calreticulin (CALR) driver mutation of essential thrombocythemia (ET) or myelofibrosis (MF)	<a href="#">NCT06150157</a>	AMC
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (PI: Duarte/25-1016)	Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review	<a href="#">NCT04910685</a>	AMC
<b>Allo Transplant/GVHD</b>			
No active trials			

Neuro-Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Clinic scheduler	-	Phone: 720-848-0300
Ana Lara-Rocha	<a href="mailto:Ana.Lararocha@uchealth.org">Ana.Lararocha@uchealth.org</a>	Phone: 720-848-9264
Physician	Email	Phone
Denise Damek, MD	<a href="mailto:Denise.damek@cuanschutz.edu">Denise.damek@cuanschutz.edu</a>	

Neuro-Oncology			
Study	Patients	NCT#	Sites
Phase I Study of [177Lu] Lu-NeoB in combination with radiotherapy and temozolomide in newly diagnosed glioblastoma and as a single agent in recurrent glioblastoma (24-0082)	Recurrent GMB	<a href="#">NCT05739942</a>	AMC (CReST)
GBM AGILE: Phase 2/3 platform trial evaluating multiple regimens for glioblastoma (19-0744)	Newly diagnosed GBM	<a href="#">NCT03970447</a>	AMC
A071401 Phase 2 study of SMO/AKT/NF2 inhibitors in progressive meningiomas (15-1747)	Progressive meningiomas with AKT1, PIK3CA or PTEN mutations	<a href="#">NCT02523014</a>	AMC
Protocol 10559 A Phase 2 study of erdafitinib in patients with recurrent or progressive IDH-wild type glioma with FGFR-TACC gene fusion (23-2578)	Recurrent and progressive gliomas	<a href="#">NCT05859334</a>	AMC
Protocol 10505, A phase 1 and randomized phase 2 trial of selinexor and temozolomide in recurrent glioblastoma (23-0099)	Glioblastoma (IDH wild-type, MGMT promoter methylated) that has undergone resection or bx upon 1 <sup>st</sup> recurrence. Has received 1L treatment of temozolomide + rt	<a href="#">NCT05432804</a>	AMC
A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1)-mutant glioma (25-1162)	Recurrent or progressive WHO Grade 2 glioma or Grade 3 glioma with IDH1 R132H or R132C mutation	<a href="#">NCT05303519</a>	AMC

Phase 1, Expansion, Molecular Studies (POEMs) Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Contact Disease Site Specific Nurse Navigator (ie Breast Cancer, GI, GU, etc.)		
Physician	Email	Phone
Jennifer Diamond, MD	jennifer.diamond@cuanschutz.edu	
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	

POEMs Studies			
Study	Patients	NCT#	Sites
Phase I study of RO7673396 (pan-RASi) as single agent and in combination with other anticancer therapy (25-0860)	Advanced solid tumors with RAS mutations	<a href="#">NCT06884618</a>	AMC
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor) (24-1841)	Advanced solid tumors with SMARCA4/BRG1 Alterations Priority NSCLC	<a href="#">NCT06561685</a>	AMC (POEMs)
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma	<a href="#">NCT03715933</a>	AMC (POEMs)
Phase 1 study of R07502175 (CCR8i)+ pembrolizumab (22-1245)	NSCLC PD-L1 $\geq$ 50%, CPI naive	<a href="#">NCT05581004</a>	AMC (POEMs)
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations (22-1125)	Metastatic CRC with BRAF V600E mutation	<a href="#">NCT05355701</a>	AMC (POEMs)
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50% 1L melanoma 2L melanoma	<a href="#">NCT05533697</a>	AMC (POEMs)
ComBET: Phase 2 trial of ZEN-3694 (BETi) + talazoparib in advanced solid tumors (23-0145)	Advanced solid tumor prior PARPi +/-DDR (not BRCA1/2) mutation	<a href="#">NCT05327010</a>	AMC (POEMs)
Phase 1 study of STX-478 (mutant selective PI3K inhibitor) (23-0200)	Metastatic HR+HER2- breast cancer with PIK3CA kinase and helical mutations	<a href="#">NCT05768139</a>	AMC (POEMs)
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic breast cancer, NSCLC (adeno and Sq Cell)	<a href="#">NCT06014658</a>	AMC (POEMs)
Phase 1 study of BG-C9074 (B7H4 ADC Topoi) +/- tislelizumab (24-1128)	Metastatic breast, endometrial and platinum resistant ovarian, no prior Topoi ADC	<a href="#">NCT06233942</a>	AMC (POEMs)
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations NSCLC G12D/V only	<a href="#">NCT06447662</a>	AMC (POEMs)
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	<a href="#">NCT06253871</a>	AMC (POEMs)
Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors (24-0554)	KRASG12C mutated NSCLC	<a href="#">NCT06128551</a>	AMC (POEMs)

Phase I study of DPTX3186 (Wnt/B-catenin inhibitor) Wnt-Pathway Activated Solid Tumors (25-2381)	Solid Tumors known to be Wnt-Pathway (CRC, Gastric, NSCLC, TNBC) activated with no other approved treatment options available	<a href="#">NCT07312903</a>	AMC (POEMs)
Phase I study of BG-C477 (CEACAM5 ADC Topoi) in Patients with Selected Advanced Solid Tumors (25-2371)	Phase 1A NSCLC treated with at least 2 prior lines Phase 1B 1L NSCLC with CEA high expression positive PD-L1 expression	<a href="#">NCT06596473</a>	AMC (POEMs)
Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)	SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy	<a href="#">NCT07080242</a>	AMC (POEMs)



Radiation Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Pam Miranda	Pamela.miranda@uchealth.org	Phone: 720-848-0224 Fax: 720-848-0113
Physician	Email	Phone
Christine Fisher, MD	<a href="mailto:Christine.fisher@cuanschutz.edu">Christine.fisher@cuanschutz.edu</a>	
Rachel Rabinovitch, MD	<a href="mailto:Rachel.Rabinovitch@cuanschutz.edu">Rachel.Rabinovitch@cuanschutz.edu</a>	

Radiation Oncology-Breast Cancer			
Study	Patients	NCT#	Sites
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0 breast cancer (19-0476)	Low-risk node+ or T3N0M0 breast cancer following surgery	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03488693">NCT03488693</a>	AMC, CCMC, HRH, LT

Radiation Oncology- Genitourinary Cancer			
NRG GU011: PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy (22-0504)	Oligometastatic hormone sensitive prostate cancer	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05053152">NCT05053152</a>	AMC, HRH
NRG-GU015: Phase 3 trial of adaptive RT + chemo for muscle invasive bladder cancer (ARCHER) (25-2502)	CT2-T3,N0M0 Urothelial carcinoma of bladder	<a href="https://clinicaltrials.gov/ct2/show/study/NCT07097142">NCT07097142</a>	AMC (RT)
S2427: Phase 2 study of bladder preservation with immunoradiotherapy after clinically meaningful response to neoadj therapy in muscle invasive bladder cancer (BRIGHT) (25-2505)	CT2-T4aN0M0 muscle invasive urothelial carcinoma of bladder	<a href="https://clinicaltrials.gov/ct2/show/study/NCT07061964">NCT07061964</a>	AMC (RT)

Radiation Oncology - Lymphoma			
Phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults (24-2065)	Newly diagnosed Stage I and II classic hodgkins lymphoma	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05675410">NCT05675410</a>	AMC

Radiation Oncology -Lung Cancer			
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC (23-1258)	Locally advanced NSCLC	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05624996">NCT05624996</a>	AMC, LT, HRH
DURABLE: Delayed or upfront brain Radiotherapy (24-1615)	naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and ALK rearrangement	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05987644">NCT05987644</a>	AMC

Radiation Oncology-Pancreatic Cancer			
<b>No currently active studies</b>			

Radiation Oncology –Neuro Oncology			
Phase I Study of [177Lu] Lu-NeoB in combination with radiotherapy and temozolomide in newly diagnosed glioblastoma and as a single agent in recurrent glioblastoma (24-0082)	Newly diagnosed and recurrent GMB	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05739942">NCT05739942</a>	AMC

Radiation Oncology-Multiple Cancer Types			
NRG-BN013: PHASE 3 study of single fraction SRS for versus FRS for intact brain metastases (24-2477)	Non-small cell lung cancer Melanoma Breast cancer Renal cell carcinoma Gastrointestinal cancer at least 1 and up to 8 total intact brain metastases and at least 1 of the up to 8 lesions must be a lesion with a maximum diameter of $\geq 1.0$ cm and $\leq 3.0$ cm	<a href="#">NCT06500455</a>	AMC
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients with Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates (25-1202)	Residual Adenocarcinoma after total neoadjuvant therapy	<a href="#">NCT07292298</a>	AMC



Sarcoma Anschutz Medical Campus (AMC)		
Nurse Navigator	Email	Phone
Erica Becker, PA-C	Erica.becker@cuanschutz.edu	Phone: 720-848-9395 Fax: 720-848-5245
Sarah Reynolds, ONN-CG, RN	Sarah.Reynolds2@uchealth.org	Phone: 720-848-0201 Fax: 720-848-0160
Marcela Mora (Spanish speaking)	<a href="mailto:Marcela.Mora@uchealth.org">Marcela.Mora@uchealth.org</a>	Phone: 720-848-5474
Physician	Email	Phone
Breelyn Wilky, MD	Breelyn.wilky@cuanschutz.edu	

Sarcoma			
Study	Patients	NCT#	Sites
Phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (25-0217)	Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas	<a href="#">NCT05711615</a>	AMC
STRASS 2 (EA7211): Phase 3 study of neoadjuvant chemo followed by surgery v surgery alone high-risk retroperitoneal sarcoma (23-1625)	High risk retroperitoneal sarcoma (LPS/LMS)	<a href="#">NCT04031677</a>	AMC
EA7222: Phase 3 trial of doxorubicin +/- pembrolizumab undifferentiated pleomorphic sarcoma (24-2043)	Undifferentiated pleomorphic sarcoma and related poorly differentiated sarcomas	<a href="#">NCT06422806</a>	AMC
Phase 1/2 study of ADI-PEG 20 or placebo plus gemcitabine and docetaxel in previously treated subjects with leiomyosarcoma (23-1728)	Leiomyosarcoma	<a href="#">NCT05712694</a>	AMC
Phase 3 double blind randomized placebo-controlled study of ivosidenib in pts over 18 yo with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (24-1378)	Locally advanced or metastatic conventional chondrosarcoma with IDH1 mutation	<a href="#">NCT06127407</a>	AMC
A Phase I/Ib Study of losartan in combination with sunitinib in the treatment of pediatric and adult patients with relapsed or refractory osteosarcoma (18-2740)	Osteosarcoma	<a href="#">NCT03900793</a>	CHCO, AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma	<a href="#">NCT03715933</a>	AMC (POEMs)
A phase II study on efficacy and tolerability of weekly doxorubicin in elderly patients (24-0118)	Advanced or Metastatic Leiomyosarcoma of Soft Tissue	<a href="#">NCT07125183</a>	AMC
Phase 1/2, open-label, dose escalation and expansion study of ADCE-D01, a humanized anti-human uPARAP antibody linked to a topoisomerase I inhibitor (24-2281)	Metastatic and/or Unresectable Soft Tissue Sarcoma	<a href="#">NCT06797999</a>	AMC
Multi-cohort, open-label, Phase 1/2 study of DCC-3009 in participants with	GIST	<a href="#">NCT06630234</a>	AMC

gastrointestinal stromal tumors (GIST) (24-2282)			
Phase 3 study of lurbinectedin + doxorubicin v. doxorubicin (SaLuDo) (25-0027)	1L metastatic leiomyosarcoma	<a href="#">NCT06088290</a>	AMC
Phase 1 study of ziftomenib + imatinib (25-0466)	GIST after imatinib failure	<a href="#">NCT06655246</a>	AMC
Expanded access to bezuclastinib + sunitinib for metastatic GIST (25-1975)	GIST that is intolerant to imatinib or received imatinib for advanced, metastatic or unresectable disease	<a href="#">NCT06948955</a>	AMC

<b>Thoracic (Lung) Oncology Anschutz Medical Campus (AMC)</b>		
<b>Nurse Navigator</b>	<b>Email</b>	<b>Phone</b>
Courtney Sorensen, RN	Courtney.thoutt@uchealth.org	Phone: 720-848-2962 Fax: 720-848-0360
<b>Physician</b>	<b>Email</b>	<b>Phone</b>
Tejas Patil, MD	Tejas.patil@cuanschutz.edu	
Erin Schenk, MD, PhD	Erin.schenk@cuanschutz.edu	

<b>Early-Stage NSCLC</b>			
<b>Study</b>	<b>Patients</b>	<b>NCT#</b>	<b>Sites</b>
NAUTIKA-1: Phase 2 study of neoadjuvant and adjuvant biomarker-selected therapy for NSCLC (22-1484)	Stage IB-III NSCLC ALK fusion, (Neoadjuvant TKIs x 8 w), PD-L1+ > 1% (atezo + SBRT) (Only ALK Fusion Cohort open)	<a href="#">NCT04302025</a>	AMC
V940-009: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (24-2314)	Neo-adjuvant (Stage II-IIIB(N2)) NSCLC	<a href="#">NCT06623422</a>	AMC
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC (23-1258)	Locally advanced NSCLC	<a href="#">NCT05624996</a>	AMC, LT, HRH (RT Group)
<b>1<sup>st</sup> Line Metastatic NSCLC</b>			
Phase 3 study of vonescimab v. pembrolizumab (25-0500)	First line Metastatic NSCLC with High PD-L1 expression	<a href="#">NCT06767514</a>	AMC
Study of response of bony metastasis for patients on TKI or systemic treatment (19-0392)	NSCLC with completed molecular testing; receiving standard of care TKI or systemic therapy for actionable driver	<a href="#">NCT03958565</a>	AMC, LT
M24-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Pembrolizumab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536) (25-0149)	Advanced/Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations	<a href="#">NCT06772623</a>	AMC
Phase 1 study of R07502175 (CCR8i) + pembrolizumab (22-1245)	NSCLC PD-L1 $\geq$ 50%, CPI naive		AMC (POEMS)
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50%	<a href="#">NCT05533697</a>	AMC (POEMS)

Phase I study of BG-C477 (CEACAM5 ADC Topoi) in Patients with Selected Advanced Solid Tumors (25-2371)	Phase 1B 1L NSCLC with CEA high expression and positive PD-L1 expression	<a href="#">NCT06596473</a>	AMC (POEMs)
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer (25-1395)	1 L NSCLC	<a href="#">NCT06892548</a>	AMC
<b>EGFR mutant NSCLC</b>			
LungMAP S1900G: Phase 2 study of osimertinib + capmatinib +/- ramucirumab (23-0936)	Metastatic NSCLC EGFR mutant with MET amplification as resistance	<a href="#">NCT05642572</a>	AMC
Systimmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoisomerase payload) in metastatic NSCLC (23-2288)	Metastatic NSCLC with EGFR mutation	<a href="#">NCT05983432</a>	AMC
Phase 1b/2 study of BG-60366 (EGFR CDAC protein degrader) for EGFRm NSCLC patients (25-0436)	Metastatic NSCLC with EGFR mutation	<a href="#">NCT06685718</a>	AMC
A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (25-1494)	Metastatic non-squamous NSCLC with classical EGFR mutation (Exon 19 Del or Exon 21 L858R). No prior EFGR TKI in locally advanced/metastatic setting	<a href="#">NCT07005102</a>	AMC
<b>ALK, ROS1, or RET rearranged NSCLC</b>			
Expanded access treatment of zidesamtinib (NVL-520) (25-0792)	Advanced ROS1+ NSCLC or other ROS1+ solid tumors	<a href="#">NCT06797362</a>	AMC
A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC (25-2822)	ALK positive NSCLC	<a href="#">NCT07491497</a>	AMC
<b>MET or HER2 altered NSCLC</b>			
SWOG S1900K: Phase 2 study of tepotinib +/- ramucirumab for MET exon 14 skip NSCLC (24-0486)	MET exon skip metastatic NSCLC	<a href="#">NCT06031688</a>	AMC
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC (23-2288)	HER2 Exon 20 mutated metastatic NSCLC	<a href="#">NCT05983432</a>	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced cancers harboring HER2 tyrosine kinase domain mutations or HER2+	<a href="#">NCT06253871</a>	AMC (POEMs)
<b>KRAS or BRAF altered NSCLC</b>			
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations, NSCLC G12D/V	<a href="#">NCT06447662</a>	AMC (POEMs)

Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors (24-0554)	KRASG12C mutated NSCLC	<a href="#">NCT06128551</a>	AMC (POEMs)
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study (25-1233)	Advanced NSCLC with KRAS G12C	<a href="#">NCT06343402</a>	AMC
<b>2<sup>nd</sup> Line and Beyond Metastatic NSCLC: ADCs, cytotoxics, radiation</b>			
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic NSCLC (adeno and SCC)	<a href="#">NCT06014658</a>	AMC (POEMs)
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (25-2371)	Phase 1A NSCLC with CEA high Expression treated with at least 2 prior lines	<a href="#">NCT06596473</a>	AMC (POEMs)
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer (25-1395)	2 L NSCLC	<a href="#">NCT06892548</a>	AMC
<b>2<sup>nd</sup> Line and Beyond Metastatic NSCLC: Immunotherapy agents and Small Molecules</b>			
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor) (24-1841)	Advanced solid tumors with SMARCA4/BRG1 Alterations	<a href="#">NCT06561685</a>	AMC (POEMs)
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist (25-2381)	Solid Tumors known to be Wnt-Pathway activated (NSCLC) with no other approved treatment options available	<a href="#">NCT07312903</a>	AMC (POEMs)
<b>Small Cell Lung Cancer</b>			
MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung (20-0359)	Small-Cell Lung Cancer	<a href="#">NCT04155034</a>	AMC, HRH
MK-6070-002: A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (25-0794)	Relapsed/Refractory Extensive-Stage SCLC	<a href="#">NCT06780137</a>	AMC
PRISM: PRecision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (25-2349)	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	<a href="#">NCT06769126</a>	AMC, North, South

<p>SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC (23-2288)</p>	<p>HER2 Exon 20 mutated metastatic NSCLC and SCLC</p>	<p><a href="#">NCT05983432</a></p>	<p>AMC</p>
<p>Phase 1 study of BL-M14D1 (DLL3-ADC) in metastatic small cell lung cancer and other neuroendocrine neoplasms (26-0037)</p>	<p>SCLC, LCNEC, NEPC, GEP-NEC, EP-NECs, MCC or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy</p>	<p><a href="#">NCT07080242</a></p>	<p>AMC (POEMs)</p>
<p>A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer (25-1395)</p>	<p>1L and 2L+ SCLC</p>	<p><a href="#">NCT06892548</a></p>	<p>AMC</p>
<p>A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants with Relapsed Small Cell Lung Cancer (25-2325)</p>	<p>Metastatic or extensive-stage small cell lung cancer</p>	<p><a href="#">NCT06179069</a></p>	<p>AMC, HRH</p>
<b>Mesothelioma and Thymic Malignancies</b>			
<p>AZ Evolve: Phase 3 study of volrustomig (PD1/CTLA4 bispecific) + chemotherapy vs investigators choice (24-0442)</p>	<p>Unresectable, untreated mesothelioma</p>	<p><a href="#">NCT06097728</a></p>	<p>AMC</p>

Satellite Site Contacts		
	Physician Leads	Nurse Navigators
CCMC	Scott Kono, MD 720-550-0270 (cell) ( <a href="mailto:Scott.Kono@CUAnschutz.edu">Scott.Kono@CUAnschutz.edu</a> )	Lanie Wolff ( <a href="mailto:lanie.wolff@uchealth.org">lanie.wolff@uchealth.org</a> ) 720-516-9254
HRH	Elaine Lam, MD ( <a href="mailto:Elaine.Lam@CUAnschutz.edu">Elaine.Lam@CUAnschutz.edu</a> )	Tera Stewart ( <a href="mailto:Tera.Stewart@CUAnschutz.edu">Tera.Stewart@CUAnschutz.edu</a> ) and Kara Ickler ( <a href="mailto:Kara.Ickler@CUAnschutz.edu">Kara.Ickler@CUAnschutz.edu</a> )
LT	Corbin Eule, MD ( <a href="mailto:Corbin.Eule@CUAnschutz.edu">Corbin.Eule@CUAnschutz.edu</a> )	Crystal Stribling ( <a href="mailto:CrystalD.Stribling@uchealth.org">CrystalD.Stribling@uchealth.org</a> )

Common Eligibility Criteria for Clinical Trials	
<b>Performance Status</b>	ECOG 0-1 Karnofsky Performance Status $\geq$ 60
<b>Age</b>	Age $\geq$ 18 years (ask for sarcoma trials)
<b>Measurable disease</b>	<p><b>Lesions that can be accurately measured in at least one dimension</b> with a minimum size requirement:</p> <ul style="list-style-type: none"> <li>• <b>For CT or MRI scans:</b> <ul style="list-style-type: none"> <li>○ The lesion must be <math>\geq</math>10 mm in its longest diameter.</li> <li>○ For lymph nodes, the short axis must be <math>\geq</math>15 mm to be considered measurable.</li> </ul> </li> <li>• <b>For physical exam or clinical measurement:</b> <ul style="list-style-type: none"> <li>○ The lesion must be <math>\geq</math>10 mm in its longest dimension and should be measurable with a caliper or ruler.</li> </ul> </li> <li>• <b>For ultrasound:</b> <ul style="list-style-type: none"> <li>○ Lesions can only be considered measurable if they are confirmed by CT or MRI measurements.</li> </ul> </li> </ul> <p><b>Non-Measurable Lesions:</b></p> <ul style="list-style-type: none"> <li>• Lesions that do not meet the criteria above are classified as <b>non-measurable</b>.</li> <li>• Please note that bone lesions (unless there is soft tissue extension), pleural effusions, or ascites are <b>not</b> considered measurable disease.</li> </ul>
<b>Adequate organ and bone marrow function</b>	<p><b>Bone marrow:</b> ANC <math>\geq</math> 1.5, Hgb <math>\geq</math> 9.0 (without recent transfusion), platelets <math>\geq</math> 100 (without recent transfusion).  <b>Hepatic:</b> AST and ALT <math>&lt;</math> 2 x ULN, bilirubin <math>&lt;</math> 2.0.  <b>Renal:</b> CrCl <math>\geq</math> 50 ml/min.  <b>Cardiovascular:</b> No symptomatic congestive heart failure; no MI, CVA, or unstable angina in the past 6 months.  <b>Pulmonary:</b> History of ILD requiring steroids (protocol dependent).  <b>Neurologic:</b> If brain metastases are present, they must have been treated and not progressing.</p>